Unicycive Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
10analysts covering
FY Revenue (est.)
$3.8Mnext fiscal year
FY EPS (est.)
-$1.42next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly57.1MTarget: Sufficient to fund planned operations into 2027
Quarterly Research and Development (R&D) Expense Quarterly1.6MTarget: Optimized to support OLC commercialization and UNI-494 development
Quarterly General and Administrative (G&A) Expense Quarterly6.8MTarget: Controlled pre-launch commercial infrastructure spending
Watch Items
- FDA PDUFA Target Action Date for Oxylanthanum Carbonate (OLC)Trigger: June 29, 2026Action: Monitor FDA decision on the Class II resubmitted NDA for OLC.
- CDMO Commercial Block Commissioning and Exhibit BatchesTrigger: Commissioning in Q4 FY2026 (Shilpa CDMO) and exhibit batches in Q1 FY2027Action: Track progress of the dedicated commercial block construction and validation with manufacturing partner Shilpa Medicare.
- UNI-494 Clinical Development ReactivationTrigger: Post-OLC approval and commercial launch stabilizationAction: Evaluate timeline and funding allocation to reactivate the UNI-494 program for acute kidney injury / delayed graft function.
Research as of 19 Jun 2026